Early Covid treatments could be a ‘bridge’ to vaccine: Fauci
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Monoclonal antibodies that stop the coronavirus from spreading in the body are among promising strategies for averting severe illness from Covid-19 before vaccines arrive, said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.

Antibody-based medications, other blood products from recovered patients and antivirals are being investigated as early treatments, Fauci said.

The aim is to prevent patients from developing serious lung damage for which Gilead Sciences Inc.’s remdesivir and the anti-inflammatory drug dexamethasone are administered.

“We are focusing very heavily now on treatment of early infection and, or prevention of infection,” Fauci told the Journal of the American Medical Association. “And that’s the bridge to the vaccine.”

With no vaccines yet proven to prevent Covid-19, health authorities must continue to push for new treatments and measures to stop the coronavirus from spreading, said Robert “Chip” Schooley, a professor of medicine at the University of California, San Diego, who is studying more potent versions of an existing antiviral.

“Optimally, we’d have an oral antiviral drug you can give to more people earlier in the course of the illness,” Schooley said. Vaccines might not be 100% effective, “which is better than nothing, but we’re still going to have to rely on drugs and behavioral modifications for a long time to come.”

Source: https://health.economictimes.indiatimes.com/news/diagnostics/early-covid-treatments-could-be-a-bridge-to-vaccine/78356166
1 share